Our analysis of LRRC59 in relation to pan-cancer immune infiltration and immunotherapy reveals a positive correlation between LRRC59 expression and TIM-3 and TIGIT, while a negative correlation with LAG-3 and PDCD1. Here, LRRC59 is linked to cancer.